Amylyx (AMLX) news
Recent news
Trading halt: Aztr (AMEX) - Regulatory concern
On October 13, 2026, trading for Aztr (AMEX) was temporarily suspended amid regulatory concerns, according to reports. While no official statement has been issued by the New York Stock Exchange, the halt has raised questions among investors about the company’s compliance status and operational…
AInvest Wire · 1d agoABionyx Pharma SA: Stifel initiates coverage with buy rating; price target EUR 8.5
Stifel has initiated coverage of ABionyx Pharma SA (ticker: AMLX) with a "Buy" rating and a price target of EUR 8.50, according to recent market updates. The firm’s decision follows a comprehensive review of the company’s pipeline, financial position, and strategic direction. While no detailed…
AInvest Wire · Sep 17, 2026Amylyx Pharmaceuticals - Bachem manufacturing agreement has initial 5 year term, auto-renews for 3 years, unless earlier terminated with its terms
AInvest Wire · Sep 8, 2026Amylyx Pharmaceuticals - To pay $30 mln upfront fee to Polypeptide for capacity reservation - SEC filing
Amylyx Pharmaceuticals has entered into an agreement with Polypeptide Laboratories, Inc., under which it will pay a $30 million upfront fee to reserve manufacturing capacity, according to a recent SEC filing [1]. The agreement is part of Amylyx's strategy to secure production capabilities for its…
AInvest Wire · Sep 8, 2026Amylyx Pharmaceuticals - Supply price under Bachem agreement to be adj annually effective Jan 1 - SEC filing
AInvest Wire · Sep 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.